Massachusetts Eye and Ear Infirmary

The Schepens Eye Research Institute, Inc.

Leo A Kim

Joseph F Arboleda-Velasquez

Dean Eliott

Luk H Vandenberghe

Patricia A D'Amore

Jason Comander

Magali Saint-Geniez

Kevin McHugh

N Grace Lee

Dhanesh Amarnani

James A Stefater

The invention provides ocular formulations and features a nano-emulsion composition, e.g., a nano-emulsion comprising a CBFβ-RUNX1 inhibitor. The composition comprises a particle with a length of less than 200 nanometers in at least one dimension.

Nano-emulsion of CBFβ-RUNX1 inhibitor for ocular drug deliver

Methods of delivering agents to structures within the eye are provided.

Methods of delivering an agent to the eye

The present subject matter provides compositions, formulations and methods for preventing or reducing proliferation or migration of retinal cells or epithelial to mesenchymal transition in ocular cells or cells from other tissues.

RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition

The invention provides ocular formulations and features a nano-emulsion composition, e.g., a nano-emulsion comprising a CBF&#x3b2;-RUNX1 inhibitor. The composition comprises a particle with a length of less than 200 nanometers in at least one dimension.

Nano-emulsion of CBF&#xdf;-RUNX1 inhibitor for ocular drug delivery

The present subject matter provides compositions, formulations, and methods for inhibiting, treating, or preventing aberrant angiogenesis in a subject.

Compositions and methods for the treatment of aberrant angiogenesis

Methods of treating acute thyroid eye disease (TED) by administering a inhibitor, e.g., a VEGF-A inhibitor, e.g., an anti-VEGF antibody, optionally in combination with hyaluronidase, by periorbital or intraorbital injection. Also compositions comprising a VEGF inhibitor and hyaluronidase.

Local orbital therapy for thyroid eye disease

In some example implementations, there is provided a method for predicting retinal degeneration in multiple eye diseases. The method may include receiving three-dimensional data representative of a plurality of layers of a retina of a subject under test; determining, from the received data, oxygen concentration at one or more of the plurality of layers; detecting, based on the determined oxygen concentration, a region of at least one a high oxygen concentration in the retina or a low oxygen concentration in the retina; and comparing the detected region to reference data to determine whether the retina including the detected region suffers from or will suffer from at least one of a retinal disease or a degeneration of the retina. Related apparatus are also disclosed.

Growing community of inventors

Boston, MA, United States of America

Leo A Kim